LUTETIUM OXODOTREOTIDE LU-177

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C65H87N14O19S2.Lu
Molecular Weight	1609.542
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LUTETIUM OXODOTREOTIDE LU-177

Structure Search

SMILES

[177Lu+3].CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O

InChI

InChIKey=MXDPZUIOZWKRAA-PRDSJKGBSA-K

InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2

HIDE SMILES / InChI

Molecular Formula	C65H87N14O19S2
Molecular Weight	1432.599
Charge	-3
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	1
Optical Activity	UNSPECIFIED

Molecular Formula	Lu
Molecular Weight	176.9438
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000lbll.pdf | https://www.ncbi.nlm.nih.gov/pubmed/29487054 | https://www.ncbi.nlm.nih.gov/pubmed/28076709

Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Somatostatin receptor 2 6 Target ID: CHEMBL1804 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22068898 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000lbll.pdf	Binding Agent 1064		1.5 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastroenteropancreatic neuroendocrine tumors 2 Sources: https://adisinsight.springer.com/drugs/800035969	Primary		Approved 8429	LUTATHERA Approved Use LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Launch Date 2018

PubMed

Title	Date	PubMed
Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.	2017 Jan 12	28076709
Lutetium Lu 177 Dotatate Approved by FDA.	2018 Apr	29487054
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.	2018 Sep 10	30383735

Patents

Sample Use Guides

In Vivo Use Guide

The recommended LUTATHERA® (lutetium Lu 177 dotatate) dose is 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.

Route of Administration: Intravenous

In Vitro Use Guide

SSTR-mediated uptake of 177Lu-DOTATATE by various cell lines was measured after 4 h incubation with 100 KBq/ml 177Lu-DOTATATE in the presence or in the absence of 1 μM octreotide

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:01:22 GMT 2023` Edited by `admin` on `Sat Dec 16 05:01:22 GMT 2023`
Record UNII	AE221IM3BB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LUTETIUM OXODOTREOTIDE LU-177

Common Name

English

LUTETATE(1-)-177LU, (N-((4,7,10-TRIS((CARBOXY-.KAPPA.O)METHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL-.KAPPA.N1,.KAPPA.N4,.KAPPA.N7,.KAPPA.N10)ACETYL)-D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-CYSTEINYL-L-THREONINE CYCLIC (2-7)-DIS

Systematic Name

English

LUTETIUM LU 177 DOTATATE

Common Name

English

177LU-DOTATATE

Common Name

English

LUTETIUM DOTATATE LU-177 [ORANGE BOOK]

Common Name

English

(177)LU-DOTATATE

Common Name

English

LUTETIUM (177LU) OXODOTREOTIDE

Official Name

English

LUTETIUM (177LU) OXODOTREOTIDE [MI]

Common Name

English

LUTETIUM-177(3+), S2,S7-CYCLO(N-(4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL)-4-CHLORO-L-PHENYLALANYL-D-CYSTEINYL-4-((4S)-2,6-DIOXO-1,3-DIAZINANE-4-CARBOXAMIDO)-L-PHENYLALANYL-4-(CARBAMOYLAMINO)-D-PHENYLALANYL-L-LYSYL-L-THREONYL-L-

Systematic Name

English

((177)LU-DOTA(0)-TYR(3))-OCTREOTATE

Common Name

English

lutetium (¹⁷⁷Lu) oxodotreotide [INN]

Common Name

English

LUTETIUM DOTATATE LU-177

Common Name

English

LUTATHERA

Brand Name

English

OXODOTREOTIDE LUTETIUM, LU-177

Common Name

English

DOTATATE LUTETIUM LU-177

Common Name

English

177LU-DOTA-TYR3-OCTREOTATE

Common Name

English

LUTETIUM LU-177 DOTATATE

Common Name

English

DOTA-OCTREOTATE LUTETIUM LU-177

Common Name

English

OXODOTREOTIDE LUTETIUM LU-177

Common Name

English

LUTETIUM DOTATATE, LU-177

Common Name

English

Lutetium (177Lu) dotatate [WHO-DD]

Common Name

English

DOTATATE LUTENIUM LU-177

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

271008